中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents

A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019

DOI: 10.3969/j.issn.1001-5256.2021.11.021
Research funding:

China National Key R&D Program (2020YFC2008301);

China National Key R&D Program (2020YFC2009001);

"National major new drug development and development" Major Science and Technology Project (2017zx09101001)

  • Received Date: 2021-03-30
  • Accepted Date: 2021-04-25
  • Published Date: 2021-11-20
  •   Objective  To investigate the use of hepatoprotective drugs in China in recent years, and to put forward related suggestions.  Methods  The outpatient prescription data of hepatoprotective drugs were collected from 85 hospitals in 6 cities of China from 2015 to 2019, and a real-world data analysis was performed to analyze the payment method, issuing department, drug category, and use of hepatoprotective drugs.  Results  A total of 1 113 575 prescriptions were extracted, involving 38 hepatoprotective drugs such as compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Hepatoprotective drugs were mainly in tertiary hospitals, and the highest number of prescriptions containing hepatoprotective drugs were observed in department of infectious diseases, department of gastroenterology, and department of tuberculosis. Anti-inflammatory hepatoprotective drugs accounted for the highest proportion of all prescriptions, mainly compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Of all prescriptions, 253 429 (22.76%) had the combination of multiple hepatoprotective drugs, with the highest number of 6 drugs, among which polyene phosphatidylcholine combined with bicyclol accounted for the highest proportion.  Conclusion  There are large quantities of hepatoprotective drugs used by outpatients in China. At present, the hepatoprotective drugs are clinically applied rationally, but there are still some problems to be solved, such as the combination of drugs.

     

  • loading
  • [1]
    LI GF, ZHANG ZY, YANG CM, et al. Classification and action of common hepatoprotective drugs[J]. China Prac Med, 2012, 7(26): 236-238. DOI: 10.14163/j.cnki.11-5547/r.2012.26.212.

    黎规丰, 张周英, 杨成密, 等. 常见保肝药的分类及作用[J]. 中国实用医药, 2012, 7(26): 236-238. DOI: 10.14163/j.cnki.11-5547/r.2012.26.212.
    [2]
    ZHAO RQ, YAO L. Present situation and evaluation of hepatoprotective drugs[J]. J Infect Dis Pharm, 2000, 10(3): 16-18. DOI: 10.13493/j.issn.1672-7878.2000.03.009.

    赵汝钦, 么玲. 保肝药的现状和评价[J]. 传染病药学, 2000, 10(3): 16-18. DOI: 10.13493/j.issn.1672-7878.2000.03.009.
    [3]
    LIU JY, ZHANG CL, LI XP, et al. Utilization analysis of hepatoprotective drugs of 34 hospitals in Wuhan area during 2012-2014[J]. Chin J Pharmacoepidemiol, 2016, 25(2): 113-118. DOI: CNKI:SUN:YWLX.0.2016-02-012.

    刘金玉, 张程亮, 李喜平, 等. 2012-2014年武汉地区34家医院保肝药应用分析[J]. 药物流行病学杂志, 2016, 25(2): 113-118. DOI: CNKI:SUN:YWLX.0.2016-02-012.
    [4]
    National Health Commission of the People's Republic of China, Medical Administration and Medical Authorit. Notice on the management of clinical application of adjuvant drugs [EB/OL]. [2018-12-12] (2020-08-27). http://www.nhc.gov.cn/yzygj/s7659/201812/bc0259007f1a4cf38cb5d0352470e33e.shtml'2018

    国家卫生健康委员会, 医政医管局. 关于做好辅助用药临床应用管理有关工作的通知[EB/OL]. [2018-12-12] (2020-08-27). http://www.nhc.gov.cn/yzygj/s7659/201812/bc0259007f1a4cf38cb5d0352470e33e.shtml'2018
    [5]
    Chinese Society of Infectious Diseases, Expert Consensus Committee on Liver Inflammation and Its Prevention and Treatment. Prevention and management of liver inflammation: An expert consensus in China[J]. Chin J Clin Infect Dis, 2014, 7(1): 4-12. DOI: 10.3760/cma.j.issn.1674-2397.2014.01.002.

    中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中华临床感染病杂志, 2014, 7(1): 4-12. DOI: 10.3760/cma.j.issn.1674-2397.2014.01.002.
    [6]
    CAO M, LI X, ZHANG B, et al. The effect of polyene phosphatidyl choline intervention on nonalcoholic steatohepatitis and related mechanism[J]. Am J Transl Res, 2016, 8(5): 2325-2330.
    [7]
    WEN XL, ZHANG HL. Literature anaiysis of adverse reactions caused by poiyene phosphatidyi choiine [J]. Chin J Pharmacov, 2020, 17(8): 526-530. DOI: 10.19803/j.1672-8629.2020.08.16.

    文晓玲, 张海浪. 多烯磷脂酰胆碱不良反应文献分析[J]. 中国药物警戒, 2020, 17(8): 526-530. DOI: 10.19803/j.1672-8629.2020.08.16.
    [8]
    YANG YL, ZHANG ZQ, WEI YQ. Clinical study on silybinin combined with polyene phosphatidylcholine for nonalcoholic fatty liver disease[J]. J New Chin Med, 2020, 52(18): 81-84. DOI: 10.13457/j.cnki.jncm.2020.19.023.

    杨亚莉, 张志强, 魏毅强. 水飞蓟宾联合多烯磷脂酰胆碱治疗非酒精性脂肪肝临床研究[J]. 新中医, 2020, 52(18): 81-84. DOI: 10.13457/j.cnki.jncm.2020.19.023.
    [9]
    CHEN JH, XU YM. Clinical effect of polyene phosphatidylcholine combined with metformin in the treatment of non-alcoholic fatty liver disease [J]. Chronic Pathematol J, 2020, 21(6): 885-886. DOI: 10.16440/j.cnki.1674-8166.2020.06.031.

    陈建辉, 许亚妹. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝临床效果[J]. 慢性病血杂志, 2020, 21(6): 885-886. DOI: 10.16440/j.cnki.1674-8166.2020.06.031.
    [10]
    CHENG ZH. Clinical effect of polyene phosphatidylcholine combined with reduced glutathione in the treatment of alcoholic hepatitis [J]. Chin J Med Devi, 2020, 33(19): 115-116. DOI: 10.14163/J.CNKI.11-5547/R.2015.09.112.

    程灶鸿. 多烯磷脂酰胆碱联合还原型谷胱甘肽治疗酒精性肝炎患者的临床效果[J]. 医疗装备, 2020, 33(19): 115-116. DOI: 10.14163/J.CNKI.11-5547/R.2015.09.112.
    [11]
    LI CY, SHI YH. Effect of polyene phosphatidylcholine on liver fibrosis and liver function of alcoholic fatty liver[J]. Hainan Med J, 2020, 31(13): 1649-1651. DOI: 10.3969/j.issn.1003-6350.2020.13.004.

    李传元, 石益海. 多烯磷脂酰胆碱对酒精性脂肪肝肝纤维化及肝功能的影响[J]. 海南医学, 2020, 31(13): 1649-1651. DOI: 10.3969/j.issn.1003-6350.2020.13.004.
    [12]
    XU H, GAO ZW, LIU JX, et al. Effect of polyene phosphatidylcholine on liver fibrosis and liver function of alcoholic fatty liver [J]. Hainan Med J, 2018, 15(4): 164-167. DOI: 10.3969/j.issn.1003-6350.2020.13.004.

    徐辉, 高志文, 刘健许, 等. 多烯磷脂酰胆碱胶囊联合还原型谷胱甘肽治疗抗结核药物致肝损伤患者的临床疗效[J]. 实用医院临床杂志, 2018, 15(4): 164-167. DOI: 10.3969/j.issn.1003-6350.2020.13.004.
    [13]
    SHI L. Analysis of the effects of polyene phosphatidylcholine combined with silybin on liver function and blood lipid levels in patients with chronic hepatitis B[J]. Chin J Pharm Econom, 2020, 15(5): 94-97. DOI: 10.12010/j.issn.1673-5846.2020.05.021.

    时岚. 多烯磷脂酰胆碱联合水飞蓟宾对慢性乙型肝炎患者肝功能及血脂水平的影响[J]. 中国药物经济学, 2020, 15(5): 94-97. DOI: 10.12010/j.issn.1673-5846.2020.05.021.
    [14]
    SHANG YH. Efficacy of bicyclol combined with polyene phosphatidylcholine in the treatment of hyperthyroid liver injury [J]. Chin J Modern Drug Appl, 2020, 14(4): 9-11. DOI: 10.14164/j.cnki.cn11-5581/r.2020.04.004.

    尚月华. 双环醇联合多烯磷脂酰胆碱治疗甲亢性肝损伤的疗效观察[J]. 中国现代药物应用, 2020, 14(4): 9-11. DOI: 10.14164/j.cnki.cn11-5581/r.2020.04.004.
    [15]
    XIE W, YU YC. Expert consensus on clinical application of bicyclol—2020 edition [J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2020, 14(3): 177-185. DOI: 10.3877/cma.j.issn.1674-1358.2020.03.001.

    谢雯, 于乐成. 双环醇临床应用专家共识——2020版[J/CD]. 中华实验和临床感染病杂志(电子版), 2020, 14(3): 177-185. DOI: 10.3877/cma.j.issn.1674-1358.2020.03.001.
    [16]
    LI H, LI JR, HUANG MH, et al. Bicyclol attenuates liver inflammation induced by infection of hepatitis C virus via repressing ROS-mediated activation of MAPK/NF-κB signaling pathway[J]. Front Pharmacol, 2018, 9: 1438. DOI: 10.3389/fphar.2018.01438.
    [17]
    LIU JL, BAI YM, TIAN GS. Progress in the application of compound glycyrrhizin in liver diseases [J]. Chin Pharm, 2006, 23: 1828-1830. DOI: 10.3969/j.issn.1001-0408.2006.23.031.

    刘君澜, 白永敏, 田庚善. 复方甘草酸苷在肝病领域的应用进展[J]. 中国药房, 2006, 23: 1828-1830. DOI: 10.3969/j.issn.1001-0408.2006.23.031.
    [18]
    DU DF, WANG RZ. Efficacy of compound glycyrrhizin with narrow-band ultraviolet radiation in the treatment of psoriasis vulgaris and its effect on cytokines and proliferation genes[J]. J Clin Exp Med, 2020, 19(3): 307-310. DOI: 10.3969/j.issn.1671-4695.2020.03.024.

    杜聃峰, 汪睿志. 复方甘草酸苷联合NB-UVB治疗寻常性银屑病的疗效及对细胞因子和增殖基因的影响[J]. 临床和实验医学杂志, 2020, 19(3): 307-310. DOI: 10.3969/j.issn.1671-4695.2020.03.024.
    [19]
    WU P. Analysis on the use of hepatoprotective drugs in inpatients in our hospital[J]. Clin Ration Drug Use, 2020, 13(2A): 109-110. DOI: 10.15887/j.cnki.13-1389/r.2020.04.063.

    吴璠. 我院住院患者保肝药使用情况分析[J]. 临床合理用药, 2020, 13(2A): 109-110. DOI: 10.15887/j.cnki.13-1389/r.2020.04.063.
    [20]
    National Healthcare Security Administration, Ministry of Human Resources and Social Security of the People's Republic of China. "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue (2020)" [EB/OL]. [2020-12-25] (2021-03-30). http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html

    国家医保局, 人力资源社会保障部. 《国家基本医疗保险、工伤保险和生育保险药品目录(2020年)》的通知[EB/OL]. [2020-12-25] (2021-03-30). http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Article Metrics

    Article views (409) PDF downloads(102) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return